TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 58 filers reported holding TCR2 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $0 | – | 85 | 0.0% | 0.00% | – |
| Q4 2022 | $0 | – | 85 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 85 | -40.6% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 143 | -92.7% | 0.00% | – |
| Q1 2022 | $5,000 | -83.9% | 1,959 | -70.4% | 0.00% | – |
| Q4 2021 | $31,000 | +14.8% | 6,625 | +113.6% | 0.00% | – |
| Q3 2021 | $27,000 | -25.0% | 3,102 | +37.7% | 0.00% | – |
| Q2 2021 | $36,000 | -29.4% | 2,253 | -1.3% | 0.00% | – |
| Q1 2021 | $51,000 | +131.8% | 2,283 | +222.9% | 0.00% | – |
| Q4 2020 | $22,000 | +2100.0% | 707 | +2180.6% | 0.00% | – |
| Q3 2020 | $1,000 | – | 31 | +29.2% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 24 | -91.3% | 0.00% | – |
| Q1 2020 | $2,000 | -86.7% | 276 | -74.3% | 0.00% | – |
| Q4 2019 | $15,000 | +1400.0% | 1,074 | +1817.9% | 0.00% | – |
| Q3 2019 | $1,000 | – | 56 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |